297 related articles for article (PubMed ID: 34187259)
1. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer.
Moussa M; Papatsoris A; Dellis A; Chakra MA; Fragkoulis C
Expert Opin Pharmacother; 2021 Dec; 22(17):2373-2381. PubMed ID: 34187259
[No Abstract] [Full Text] [Related]
2. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial.
Dearnaley DP; Saltzstein DR; Sylvester JE; Karsh L; Mehlhaff BA; Pieczonka C; Bailen JL; Shi H; Ye Z; Faessel HM; Lin H; Zhu Y; Saad F; MacLean DB; Shore ND
Eur Urol; 2020 Aug; 78(2):184-192. PubMed ID: 32273183
[TBL] [Abstract][Full Text] [Related]
3. An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.
Roy S; Zaorsky NG; Bagshaw HP; Berlin A; Tree A; Turner S; Koontz B; Nguyen P; Chen R; Dess RT; Jackson WC; Kishan AU; Stish B; Nagar H; Posadas E; Tran PT; Solanki A; Shore ND; Guo G; Ponsky L; Shoag JE; Morgans AK; Garcia JA; Showalter TN; Feng FY; Spratt DE
Int J Radiat Oncol Biol Phys; 2022 Jun; 113(2):278-289. PubMed ID: 34923058
[TBL] [Abstract][Full Text] [Related]
4. Relugolix: A Review in Advanced Prostate Cancer.
Shirley M
Target Oncol; 2023 Mar; 18(2):295-302. PubMed ID: 36652173
[TBL] [Abstract][Full Text] [Related]
5. Degarelix versus luteinizing hormone-releasing hormone agonists for the treatment of prostate cancer.
Clinton TN; Woldu SL; Raj GV
Expert Opin Pharmacother; 2017 Jun; 18(8):825-832. PubMed ID: 28480768
[TBL] [Abstract][Full Text] [Related]
6. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer.
Saad F; Shore ND
Ther Adv Med Oncol; 2021; 13():1758835921998586. PubMed ID: 34408793
[TBL] [Abstract][Full Text] [Related]
7. Advances with androgen deprivation therapy for prostate cancer.
Yu EM; Aragon-Ching JB
Expert Opin Pharmacother; 2022 Jun; 23(9):1015-1033. PubMed ID: 35108137
[TBL] [Abstract][Full Text] [Related]
8. New treatment paradigm for prostate cancer: abarelix initiation therapy for immediate testosterone suppression followed by a luteinizing hormone-releasing hormone agonist.
Garnick MB; Mottet N
BJU Int; 2012 Aug; 110(4):499-504. PubMed ID: 22093775
[TBL] [Abstract][Full Text] [Related]
9. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer.
George DJ; Dearnaley DP
Future Oncol; 2021 Nov; 17(33):4431-4446. PubMed ID: 34409852
[TBL] [Abstract][Full Text] [Related]
10. A comparative study on the efficacies of gonadotropin-releasing hormone (GnRH) agonist and GnRH antagonist in neoadjuvant androgen deprivation therapy combined with transperineal prostate brachytherapy for localized prostate cancer.
Miki K; Sasaki H; Kido M; Takahashi H; Aoki M; Egawa S
BMC Cancer; 2016 Sep; 16(1):708. PubMed ID: 27586506
[TBL] [Abstract][Full Text] [Related]
11. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists.
Shore ND; Abrahamsson PA; Anderson J; Crawford ED; Lange P
Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):7-15. PubMed ID: 22751146
[TBL] [Abstract][Full Text] [Related]
12. Does Exist a Differential Impact of Degarelix
Sciarra A; Busetto GM; Salciccia S; Del Giudice F; Maggi M; Crocetto F; Ferro M; De Berardinis E; Scarpa RM; Porpiglia F; Carmignani L; Damiano R; Artibani W; Carrieri G
Front Endocrinol (Lausanne); 2021; 12():695170. PubMed ID: 34194398
[TBL] [Abstract][Full Text] [Related]
13. The Efficacy and Safety of Relugolix Compared with Degarelix in Advanced Prostate Cancer Patients: A Network Meta-analysis of Randomized Trials.
Sari Motlagh R; Abufaraj M; Mori K; Aydh A; Rajwa P; Katayama S; Grossmann NC; Laukhtina E; Mostafai H; Pradere B; Quhal F; Karakiewicz PI; Enikeev DV; Shariat SF
Eur Urol Oncol; 2022 Apr; 5(2):138-145. PubMed ID: 34301529
[TBL] [Abstract][Full Text] [Related]
14. [Cardiovascular risk patients under androgen deprivation therapy: Lower risk with GnRH antagonists compared to LHRH agonists?].
Merseburger AS; Sedding D; Hüter K
Urologe A; 2016 Feb; 55(2):218-25. PubMed ID: 26637324
[TBL] [Abstract][Full Text] [Related]
15. Progress in Clinical Research on Gonadotropin-Releasing Hormone Receptor Antagonists for the Treatment of Prostate Cancer.
Liu YF; Fu SQ; Yan YC; Gong BB; Xie WJ; Yang XR; Sun T; Ma M
Drug Des Devel Ther; 2021; 15():639-649. PubMed ID: 33623372
[TBL] [Abstract][Full Text] [Related]
16. Gonadotropin-Releasing Hormone Antagonists in Prostate Cancer.
Kittai AS; Blank J; Graff JN
Oncology (Williston Park); 2018 Dec; 32(12):599-602, 604-6. PubMed ID: 30632129
[TBL] [Abstract][Full Text] [Related]
17. Bench-to-bedside development of agonists and antagonists of luteinizing hormone-releasing hormone for treatment of advanced prostate cancer.
Rick FG; Schally AV
Urol Oncol; 2015 Jun; 33(6):270-4. PubMed ID: 25512159
[TBL] [Abstract][Full Text] [Related]
18. Abarelix and other gonadotrophin-releasing hormone antagonists in prostate cancer.
Kirby RS; Fitzpatrick JM; Clarke N
BJU Int; 2009 Dec; 104(11):1580-4. PubMed ID: 20053189
[TBL] [Abstract][Full Text] [Related]
19. Relugolix in the management of prostate cancer.
Sahu KK; Tripathi N; Agarwal N; Swami U
Expert Rev Anticancer Ther; 2022 Sep; 22(9):891-902. PubMed ID: 35866612
[TBL] [Abstract][Full Text] [Related]
20. [Cardiovascular risk of androgen deprivation therapy for treatment of hormone-dependent prostate cancer : Differences between GnRH antagonists and GnRH agonists].
Tschöpe C; Kherad B; Spillmann F; Schneider CA; Pieske B; Krackhardt F
Herz; 2016 Dec; 41(8):697-705. PubMed ID: 27083586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
